Scroll Top

Publikacje pełnotekstowe

Publikacje pełnotekstowe

Publikacje pełnotekstowe

  1. Śladowska K, Moćko P, Brzostek T, Kawalec P. Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies. Mult Scler Relat Disord. 2025 Jan 7;94:106263. doi: 10.1016/j.msard.2025.106263.
  2. Jakubowski S, Holko P, Nowak R, et al. Kawalec P. Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries. Front Pharmacol. 2024 Nov 19;15:1498386. doi: 10.3389/fphar.2024.1498386.
  3. Moćko P, Koperny M, Śladowska K, Holko P, Kowalska-Bobko I, Kawalec P. Efficacy and safety of mirikizumab compared with currently approved biologic drugs for the treatment of ulcerative colitis: A systematic review and network meta-analysis. Pharmacotherapy. 2024 Sep 25. doi: 10.1002/phar.4611.
  4. Kowalska M, Sitarz-Kilian E, Jaros K, Koperny M, Moćko P, Siwiec J, Kawalec P. Evidence for external beam radiotherapy in mediastinal Hodgkin and non-Hodgkin lymphoma – systematic review. Ann Agric Environ Med. 2024 Mar 25;31(1):47-56. doi: 10.26444/aaem/168272.
  5. Jakubowski S, Kawalec P, Holko P, Kowalska-Bobko I, Kamusheva M, Petrova G, Draganić P, Fuksa L, Männik A, Ispán F, Briedis V, Bianchi I, Paveliu MS, Tesar T. Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries. Front Pharmacol. 2024 Mar 8;15:1369178. doi: 10.3389/fphar.2024.1369178.
  6. Moćko P, Rudź R, Siwiec J Kawalec P, Koperny M, Pełech Pa. Budget Impact Analysis for Proton Beam Therapy for pediatric population in Poland. Journal of Health Policy & Outcomes Research 2023: 1. doi:10.7365/jhpor.2023.1.3
  7. Krawczyk K, Śladowska K, Holko P, Kawalec P. Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma : a systematic review and network meta-analysis. Frontiers in Pharmacology 2023: 14, 1223929.
  8. Holko P, Kawalec P, Sajak-Szczerba M, Avedano L, Mossakowska M. Indirect Costs of Inflammatory Bowel Diseases : a comparison of patient-reported outcomes across 12 European Countries. Inflammatory Bowel Diseases 2023: 29(5), 752-762.
  9. Śladowska K, Kawalec P, Brzostek T, Pilc A. Potential use of psilocybin drugs in the treatment of depression. Expert Opinion on Emerging Drugs 2023: 28(4), 241-256.
  10. Moćko P, Śladowska K, Kawalec P, Babii Y, Pilc A. The potential of scopolamine as an antidepressant in major depressive disorder : a systematic review of randomized controlled trials. Biomedicines 2023: 11(10), 2636.
  11. Śladowska K, Kawalec P, Holko P, Osiecka O. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis : a systematic review and network meta-analysis. Neurological Sciences 2022: 43, 5479-5500.
  12. Blonda A, Denier Y, Huys I, Kawalec P, Simoens S. How can we optimize the value assessment and appraisal of orphan drugs for reimbursement purposes? A qualitative interview study across European countries. Frontiers in Pharmacology 2022: 13, 902150.
  13. Żegleń M, Śladowska K, Kawalec P, Brzostek T. Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinsons disease : a systematic review and meta-analysis. Journal of Comparative Effectiveness Research 2022: 11(12), 889-904.
  14. Holko P, Kawalec P, Sajak-Szczerba M, Avedano L, Mossakowska M. Out-of-pocket expenses of patients with inflammatory bowel disease : a comparison of patient-reported outcomes across 12 European countries. European Journal of Health Economics 2022: 24(7), 1073-1083.
  15. Kawalec P, Holko P, Bungey G, Moseley O, Żegleń M, Markiewicz M. Treosulfan-based conditioning vs. low-dose busulfan-based conditioning for allogeneic hematopoietic stem cell transplantation : a cost-utility analysis in Poland. Acta Haematologica Polonica 2022: 53(3), 191-200.
  16. Pilc A, Machaczka A, Kawalec P, Smith JL, Witkin JM. Where do we go next in antidepressant drug discovery? A new generation of antidepressants : a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism. Expert Opinion on Drug Discovery 2022: 17(10), 1131-1146.
  17. Holko P, Kawalec P. Wykorzystanie baz danych Narodowego Funduszu Zdrowia przy ocenie dowodów naukowych z praktyki klinicznej. Zeszyty Naukowe Ochrony Zdrowia, Zdrowie Publiczne i Zarządzanie 2022: 20(2), 25-33.
  18. Tesar T, Golias P, Masarykova L, Kawalec P, Inotai A. The Impact of reimbursement practices on the pharmaceutical market for off-patent medicines in Slovakia. Frontiers in Pharmacology 2021: 12, 795002.
  19. Panek M, Kawalec P, Pilc A, Lasoń W. Developments in the discovery and design of intranasal antidepressants. Expert Opinion on Drug Discovery 2020: 15(10), 1145-1164.
  20. Kryst J, Kawalec P, Pilc A. Efficacy and Safety of Intranasal Esketamine for the Treatment of Major Depressive Disorder. Expert Opinion on Pharmacotherapy 2020: 21(1), 9-20.
  21. Kryst J, Kawalec P, Mikrut Mitoraj A, Pilc A, Lasoń Władysław, Brzostek Tomasz. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression : a meta-analysis of randomized clinical trials. Pharmacological Reports 2020: 72(3), 543-562.
  22. Panek M, Kawalec P, Malinowska-Lipień I, Brzostek T, Pilc A. Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets. Expert Opinion on Therapeutic Targets 2020: 24(12), 1187-1209.
  23. Malinowski Krzysztof P, Kawalec P, Trąbka W, Sowada Ch, Petrova G, Manova M, Savova A, Draganić P, Slaby J, Mannik A, Marky K, Rugaja Z, Gulbinovic J, Tesar T, Paveliu MS. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe. Orphanet Journal of Rare Diseases 2020: 15(1), 277.
  24. Tesar T, Golias P, Kobliskova Z, Wawruch M, Kawalec P, Inotal A. Potential Cost-Savings From the Use of the Biosimilars in Slovakia. Frontiers in Public Health 2020: 8, 431.
  25. Stawowczyk E, Kawalec P, Kowalska-Duplaga K, Mossakowska M. Productivity Loss Among Parents of Children with Inflammatory Bowel Diseases in Relation to Disease Activity and Patient’s Quality of Life. Journal of Pediatric Gastroenterology and Nutrition 2020: 71(3), 340-345.
  26. Kawalec P, Śladowska K, Malinowska-Lipień I, Brzostek T, Kózka M. New alternative in the treatment of rheumatoid arthritis: clinical utility of of baricitinib. Therapeutics and Clinical Risk Management 2019: 15, 275-284
  27. Malinowski KP, Kawalec P, Trąbka W, Czech M, Petrova G, Manova M, Savova A, Draganic P, Vostalova L, Slaby J, Mannik A, Marky K, Rugaja Z, Gulbinovic J, Tesar T, Paveliu MS. Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries. Frontiers in Pharmacology: 2019: 10, 487.
  28. Stawowczyk E, Malinowski KP, Kawalec P, Bobiński R, Siwiec J, Panteli D, Eckhardt H, Simoens S, Agusti A, Dooms M, Pilc A. Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries. Frontiers in Pharmacology: 2019: 10, 1279.
  29. Tesar T, Golias P, Inotai A, Kawalec P, Wawruch M. The impact of implemented regulations on biosimilars in Slovakia. Health Policy and Technology: 2019: 8(4), 408-413.
  30. Stawowczyk E, Kawalec P. A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis. Pharmacoeconomics: 2018: 36(4), 419-434.
  31. Kawalec P, Moćko P. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn’s disease patients. Journal of Comparative Effectiveness Research: 2018: 7(2), 101-111.
  32. Kamusheva M, Manova M, Savova AT, Petrova GI, Mitov K, Harsanyi A, Kalo Z, Marky K, Kawalec P, Angelovska B, Lakic D, Tesar T, Draganic P, Geitona M, Hatzikou M, Paveliu MS, Mannik A. Comparative analysis of legislative requirements about patients’ access to biotechnological drugs for rare diseases in Central and Eastern European Countries. Frontiers in Pharmacology: 2018: 9, 975.
  33. Kawalec P, Holko P, Moćko P, Pilc S. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Rheumatology International: 2018: 38 (2), 189-201.
  34. Holko P, Kawalec P, Pilc A. Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Pharmacoeconomics 2018: 36(7), 853-865.
  35. Kawalec P, Holk P, Gawin M, Pilc A. Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis. Archives of Medical Science: 2018: 14(5), 1125-1136.
  36. Kawalec P, Śladowska K, Malinowska-Lipień I, Brzostek T, Kózka M. European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib. Therapeutics and Clinical Risk Management: 2018: 14, 15-29.
  37. Kawalec P, Mrożek-Gąsiorowska MA, Stawowczyk E. Health technology assessment of medical devices. Zeszyty Naukowe Ochrony Zdrowia, Zdrowie Publiczne i Zarządzanie: 2018: 16(3), 187-194.
  38. Holko P, Kawalec P, Pilc A. Impact of Biologic Treatment of Crohn’s Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland. Frontiers in Pharmacology: 2018: 9, (621), 1-7.
  39. Holko P, Kawalec P, Stawowczyk E. Prevalence and drug treatment practices of inflammatory bowel diseases in Poland in the years 2012-2014: an analysis of nationwide databases. European Journal of Gastroenterology & Hepatology: 2018: 30, (4), 456-464.
  40. Holko P, Kawalec P, Mossakowska M. Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: a time trade-off study. European Journal of Gastroenterology & Hepatology 2018: 30(2), 174-180.
  41. Malinowski KP, Kawalec P, Trabka T, Sowada Ch, Pilc A. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment. Frontiers in Pharmacology: 2018: 9, 1263.
  42. Kawalec P, Stawowczyk E. Relationship between physician-based assessment of disease activity, quality of life, and costs of ulcerative colitis in Poland. Przegląd Gastroenterologiczny: 2018: 13(1), 61-68.
  43. Szegedi M, Zelei T, Arickx F, Bucsics A, Cohn-Zanchetta E, Furst J, Kamusheva M, Kawalec P, Petrova G, Slaby J, Stawowczyk E, Vocelka M, Zechmeister-Koss I, Kalo Z, Molnar MJ. The European challenges of funding orphan medicinal products. Orphanet Journal of Rare Diseases 2018:13, 184, 1-8.
  44. Kawalec P, Malinowski KP, Trąbka W. Trends and determinants in reimbursement decision-making in Poland in the years 2013-2015. Expert Review of Pharmacoeconomics & Outcomes Research 2018: 18(2), 197-205.